V Wealth Advisors’s Cascadian Therapeutics, Inc. CASC Stock Holding History

V Wealth Advisors’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-83	Closed	–	–	818
2017 Q2	$0	Buy	+83	New	+$329	﹤0.01%	848

Other funds holding CASC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return

V Wealth Advisors's CASC Position: Q3 2017 in Review

V Wealth Advisors sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2017, closing a stake of 83 shares.

V Wealth Advisors first reported a position in CASC in Q2 2017 and held it in 1 quarter. The position peaked at $0 in Q2 2017. 79 funds tracked by Wall St. Rank hold CASC as of Q3 2017.

V Wealth Advisors reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
V Wealth Advisors sold 83 Cascadian Therapeutics, Inc. shares in Q3 2017.
V Wealth Advisors first reported a position in Cascadian Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
V Wealth Advisors's Cascadian Therapeutics, Inc. position peaked at $0 in Q2 2017.
79 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2017.

Based on V Wealth Advisors's 13F filing for Q3 2017, filed 12 Oct 2017.